2017
DOI: 10.7150/thno.20168
|View full text |Cite
|
Sign up to set email alerts
|

Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery

Abstract: Chemotherapy-resistant cancer stem cells (CSCs) are a major obstacle to the effective treatment of many forms of cancer. To overcome CSC chemo-resistance, we developed a novel system by conjugating a CSC-targeting EpCAM aptamer with doxorubicin (Apt-DOX) to eliminate CSCs. Incubation of Apt-DOX with colorectal cancer cells resulted in high concentration and prolonged retention of DOX in the nuclei. Treatment of tumour-bearing xenograft mice with Apt-DOX resulted in at least 3-fold more inhibition of tumour gro… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
49
0

Year Published

2019
2019
2020
2020

Publication Types

Select...
5
1
1

Relationship

1
6

Authors

Journals

citations
Cited by 73 publications
(52 citation statements)
references
References 77 publications
3
49
0
Order By: Relevance
“…These conjugates have been produced by either covalent or noncovalent conjugation through intercalation . Through self‐assembly by noncovalent integration of doxorubicin into engineered DNA–RNA hybrid EpCAM aptamer, this drug‐aptamer conjugate was able to effectively target colorectal CSCs, internalize and deliver the drug to the nuclei of CSCs in vivo . In addition, Duan lab pioneered aptamer‐guided in vivo delivery of siRNA into CSCs by engineering a chimera of EpCAM aptamer and a 27 mer Dicer substrate survivin siRNA ( Figure A–F).…”
Section: Aptamer Emerges As a Prominent Targeting Ligand For Nanodelimentioning
confidence: 99%
“…These conjugates have been produced by either covalent or noncovalent conjugation through intercalation . Through self‐assembly by noncovalent integration of doxorubicin into engineered DNA–RNA hybrid EpCAM aptamer, this drug‐aptamer conjugate was able to effectively target colorectal CSCs, internalize and deliver the drug to the nuclei of CSCs in vivo . In addition, Duan lab pioneered aptamer‐guided in vivo delivery of siRNA into CSCs by engineering a chimera of EpCAM aptamer and a 27 mer Dicer substrate survivin siRNA ( Figure A–F).…”
Section: Aptamer Emerges As a Prominent Targeting Ligand For Nanodelimentioning
confidence: 99%
“…We interrogated CMap utilizing the gene expression signatures from SHH MB samples with high and low mRNAsi levels. The CMap analysis precisely identified some compounds that have been shown to specifically impact CSCs in other tumor types (Angeletti et al, 2016;Batsaikhan et al, 2014;Battula et al, 2017;Bonuccelli et al, 2017;Bozok Cetintas et al, 2016;Chen et al, 2015Chen et al, , 2016Cheng et al, 2017;Dominguez-Gomez et al, 2018;Garulli et al, 2014;Hong et al, 2011;Hou et al, 2018;Malkomes et al, 2016;Xiang et al, 2017;Xu et al, 2016;Yeh et al, 2013;Yin et al, 2018;You et al, 2009;Zhang et al, 2013;Zheng et al, 2013a,b). These compounds include the CDK inhibitors palbociclib and alvocidib, the AMPK inhibitor dorsomorphin, the IKK inhibitor BMS-345541, the smoothened receptor antagonist cyclopamine, the topoisomerase inhibitors topotecan and doxorubicin, the GABA receptor agonist ivermectin, the NF-jB pathway inhibitor auranofin, the MTOR inhibitor dactolisib, the AKT inhibitors MK-2206 and pyrvinium-pamoate, the HMGCR inhibitor simvastatin, the HDAC inhibitors apicidin, vorinostat, and givinostat, and the DNA synthesis inhibitor anisomycin.…”
Section: Correlation Of the Immune Cells With Mdnasimentioning
confidence: 99%
“…The microbiota seems to include a variety of bacterial species and many of them have yet to be characterized. Nevertheless, the bacterial pathogens leading to inflammatory disorders have one thing in common; they all employ several mechanisms to overcome the human immune cells and are hard to be removed naturally …”
Section: Biofilm and Chronic Inflammatory Diseasementioning
confidence: 99%